Status:

COMPLETED

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma

Lead Sponsor:

Eisai Co., Ltd.

Collaborating Sponsors:

Ono Pharmaceutical Co. Ltd

Conditions:

Carcinoma, Hepatocellular

Eligibility:

All Genders

20+ years

Phase:

PHASE1

Brief Summary

The primary objective of this study is to evaluate the tolerability and safety of a combination of lenvatinib plus nivolumab in participants with hepatocellular carcinoma (HCC).

Eligibility Criteria

Inclusion

  • Participants must have confirmed diagnosis of hepatocellular carcinoma (HCC) with any of the following criteria:
  • Histologically or cytologically confirmed diagnosis of HCC, excluding fibrolamellar, sarcomatoid or mixed cholangio-HCC tumors
  • Clinically confirmed diagnosis of HCC according to American Association for the Study of Liver Diseases criteria, including cirrhosis of any etiology and/or chronic hepatitis B or C infection
  • Part 1: HCC for which no other appropriate therapy is available; Part 2: No prior systemic therapy for advanced/unresectable HCC
  • Participants categorized to stage B (not applicable for transarterial chemoembolization), or stage C based on Barcelona Clinic Liver Cancer staging system
  • Child-Pugh score A
  • Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 to 1
  • Age greater than or equal to (\>=) 20 years at the time of informed consent

Exclusion

  • Active co-infection with hepatitis B and hepatitis C
  • Participants with any active, known, or suspected autoimmune disease
  • Participants being treated with drugs that strongly inhibit or induce CYP3A4 and that may be possibly used during this study
  • Females who are breastfeeding or pregnant

Key Trial Info

Start Date :

January 16 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 28 2022

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT03418922

Start Date

January 16 2018

End Date

December 28 2022

Last Update

June 20 2024

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Eisai Trial Site 1

Kashiwa, Chiba, Japan

2

Eisai Trial Site 6

Iizuka, Fukuoka, Japan

3

Eisai Trial Site 3

Kawasaki, Kanagawa, Japan

4

Eisai Trial Site 4

Sayama, Osaka, Japan